Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2013. The report specifically addresses a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) related to the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding internal plan allocations rather than a financial results report.
Material Changes
No material changes to the company's financial position or operations are reported. The document details a revaluation of the cash element of a notional investment held within the GSK 401K plan, resulting in an increase in the notional allocation of American Depositary Shares (ADSs) on September 13, 2013, at a price of $51.41 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Type: Increase in notional ADS allocation within the GSK 401K plan due to revaluation.
- Transaction Date: September 13, 2013.
- Price per ADS: $51.41.
- Individuals Involved: Dr. M. Slaoui (Director) and Dr. K. Slaoui (Connected Person).
- Allocation Details: Dr. M. Slaoui received no additional ADSs; Dr. K. Slaoui received 4 ADSs.
- Financial Data: No financial performance metrics are included in this specific filing.